Interleukin-6 serum levels are associated with disease features and cardiovascular risk in patients with systemic sclerosis

被引:0
|
作者
Ibrahim-Achi, Z. [1 ]
de Vera-Gonzalez, A. [2 ]
Gonzalez-Delgado, A. [2 ]
Lopez-Mejias, R. [3 ]
Gonzalez-Gay, M. A. [3 ,4 ,5 ]
Ferraz-Amaro, I. [6 ,7 ]
机构
[1] Hosp Univ Canarias, Div Angiol & Vasc Surg, Tenerife, Spain
[2] Hosp Univ Canarias, Div Cent Lab, Tenerife, Spain
[3] IDIVAL, Epidemiol Genet & Atherosclerosis Res Grp Syst Inf, Santander, Spain
[4] IIS Fdn Jimenez Diaz, Div Rheumatol, Ave los Reyes Catolicos 2, Madrid 28040, Spain
[5] Univ Cantabria, IDIVAL, Santander, Spain
[6] Univ La Laguna ULL, Dept Internal Med, Tenerife, Spain
[7] Hosp Univ Canarias, Div Rheumatol, Tenerife 38320, Spain
关键词
systemic sclerosis; scleroderma; interleukin-6; SCORE2; CORONARY-HEART-DISEASE; TOCILIZUMAB; RECEPTOR; TRIALS;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Systemic sclerosis (SSc) is a chronic multisystem disease characterised by microcirculatory vascular dysfunction and progressive fibrosis of the skin and internal organs. Interleukin-6 (IL-6) is a proinflammatory cytokine that has been implicated in the pathogenesis of several autoimmune diseases and in the initiation and progression of the cardiovascular disease. In the present work we aimed to study the relationship of IL-6 with clinical manifestations and the cardiovascular risk in patients with SSc. Methods We carried out a cross-sectional study that included 53 individuals with SSc. A multivariate analysis was performed to study the relationship between IL-6 and disease characteristics and cardiovascular risk assessed by Systematic Coronary Risk Estimation (SCORE2) in SSc. Results The presence of digital ulcers, calcinosis, and anti-Scl70 antibody was associated with higher levels of IL-6. This was also the case for functional respiratory parameters where this association was found to be significant and negative after correction for covariates. In addition, the SCORE2 cardiovascular risk algorithm showed a positive and significant association with circulating IL-6. Conclusion IL-6 levels are associated with disease manifestations and cardiovascular risk in patients with SSc.
引用
收藏
页码:1564 / 1570
页数:7
相关论文
共 50 条
  • [1] SERUM INTERLEUKIN-6 IN SYSTEMIC SCLEROSIS AND ITS CORRELATION WITH DISEASE PARAMETERS AND CARDIOPULMONARY INVOLVEMENT
    Abdel-Magied, Rasha A.
    Kamel, Shereen R.
    Said, Azza Farag
    Ali, Hazem M.
    Gawad, Ehab A. Abdel
    Moussa, Mahmoud M.
    SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2016, 33 (04) : 321 - 330
  • [2] Serum Interleukin-6, Interleukin-17A, and Transforming Growth Factor Beta Are Raised in Systemic Sclerosis with Interstitial Lung Disease
    Wakhlu, Anupam
    Sahoo, Rasmi Ranjan
    Parida, Jyoti Ranjan
    Rai, Mohit K.
    Misra, Durga P.
    Agrawal, Vinita
    Agarwal, Vikas
    INDIAN JOURNAL OF RHEUMATOLOGY, 2018, 13 (02) : 107 - 112
  • [3] High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis
    Uzawa, Akiyuki
    Akamine, Hiroyuki
    Kojima, Yuta
    Ozawa, Yukiko
    Yasuda, Manato
    Onishi, Yosuke
    Sawai, Setsu
    Kawasaki, Kenji
    Asano, Haruna
    Ohyama, Satoko
    Matsushita, Kazuyuki
    Mori, Masahiro
    Kuwabara, Satoshi
    JOURNAL OF NEUROIMMUNOLOGY, 2021, 358
  • [4] The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis
    Shima, Yoshihito
    MODERN RHEUMATOLOGY, 2019, 29 (02) : 294 - 301
  • [5] Serum Levels of Interleukin-6 and Interleukin-10 in Relation to Depression Scores in Patients with Cardiovascular Risk Factors
    Meyer, Thomas
    Stanske, Beate
    Kochen, Michael M.
    Cordes, Andreas
    Yueksel, Iraz
    Wachter, Rolf
    Lueers, Claus
    Scherer, Martin
    Binder, Lutz
    Pieske, Burkert
    Herrmann-Lingen, Christoph
    BEHAVIORAL MEDICINE, 2011, 37 (03) : 105 - 112
  • [6] Interleukin-6 Serum Levels in Patients with Parkinson's Disease
    Hofmann, Kerly Wollmeister
    Schumacher Schuh, Artur Francisco
    Saute, Jonas
    Townsend, Raquel
    Fricke, Daniele
    Leke, Renata
    Souza, Diogo O.
    Portela, Luis Valmor
    Fagundes Chaves, Marcia Lorena
    Rieder, Carlos R. M.
    NEUROCHEMICAL RESEARCH, 2009, 34 (08) : 1401 - 1404
  • [7] Intrathecal interleukin-6 levels are associated with progressive disease and clinical severity in multiple sclerosis
    Itorralba, Justine
    Brand-Arzamendi, Koroboshka
    Saab, Georges
    Muccilli, Alexandra
    Schneider, Raphael
    BMC NEUROLOGY, 2025, 25 (01)
  • [8] Cytokine imbalance in patients with systemic sclerosis and resilience: the key role of interleukin-6
    Rojas, M.
    Rodriguez, Y.
    Monsalve, D. M.
    Pacheco, Y.
    Acosta-Ampudia, Y.
    Rodriguez-Jimenez, M.
    Molano-Gonzalez, N.
    Mantilla, R. D.
    Ramirez-Santana, C.
    Anaya, J. -M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (04) : S15 - S22
  • [9] Interleukin-6 Serum Levels in Patients with Parkinson’s Disease
    Kerly Wollmeister Hofmann
    Artur Francisco Schumacher Schuh
    Jonas Saute
    Raquel Townsend
    Daniele Fricke
    Renata Leke
    Diogo O. Souza
    Luis Valmor Portela
    Márcia Lorena Fagundes Chaves
    Carlos R. M. Rieder
    Neurochemical Research, 2009, 34 : 1401 - 1404
  • [10] ELEVATED SERUM INTERLEUKIN-6 LEVELS ASSOCIATED WITH ACTIVE DISEASE IN SYSTEMIC CONNECTIVE-TISSUE DISORDERS
    STUART, RA
    LITTLEWOOD, AJ
    MADDISON, PJ
    HALL, ND
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1995, 13 (01) : 17 - 22